Potent covalent irreversible inhibitor of KRAS G12C IBI351 in patients with advanced solid tumors: First-in-human phase I study. Zhou Q, Yang N, Zhao M, Huang D, et al. Eur J Cancer 2024;212:114337.

Read + Share

Amedeo Smart

Independent Medical Education

Read + Share

Zhou Q, Yang N, Zhao M, Huang D, et al. Potent covalent irreversible inhibitor of KRAS G12C IBI351 in patients with advanced solid tumors: First-in-human phase I study. Eur J Cancer 2024;212:114337.
PMID: 39357276